Sun Pharma Launches UNLOXCYT for Unresectable Skin Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Source: PRnewswire
- New Drug Launch: Sun Pharma announces the official launch of UNLOXCYT (cosibelimab-ipdl) in the U.S., providing a new treatment option for patients with unresectable or radiation-resistant metastatic cutaneous squamous cell carcinoma, marking a significant advancement in the company's oncology portfolio.
- Clinical Efficacy: Data from the CK-301-101 clinical trial shows a disease control rate of 71% for UNLOXCYT, with 13% of metastatic CSCC patients achieving complete response, highlighting its substantial efficacy in treatment.
- Patient Support Program: Sun Pharma introduces the UNLOXCYT SUPPORT patient access and affordability program, ensuring that patients can access the drug from day one of its launch, reflecting the company's strong commitment to patient needs.
- Safety Information: The safety profile of UNLOXCYT remains consistent with the original label, with common adverse reactions including fatigue and musculoskeletal pain, and no cases of Grade 3 or 4 pneumonitis reported, indicating good tolerability of the drug.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SUN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SUN
Wall Street analysts forecast SUN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUN is 63.67 USD with a low forecast of 57.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 58.440
Low
57.00
Averages
63.67
High
70.00
Current: 58.440
Low
57.00
Averages
63.67
High
70.00
About SUN
Sunoco LP is an energy infrastructure and fuel distribution master limited partnership operating in over 32 countries and territories in North America, the Greater Caribbean, and Europe. The Company's midstream operations include a network of approximately 14,000 miles of pipeline and over 160 terminals. Its segments include Fuel Distribution, Pipeline Systems and Terminals. The Fuel Distribution segment supplies motor fuel to independently operated dealer stations, distributors, commission agents and other consumers. The Pipeline Systems segment includes the operations of its refined products, crude oil and anhydrous ammonia pipelines, as well as other assets that are operated and managed on an integrated basis with its pipeline systems, including certain terminal and storage assets. Its Terminals segment is composed of facilities that provide storage, handling and other services on a fee basis for refined products, crude oil, specialty chemicals, renewable fuels and other liquids.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Germany Mandates Sale of Key Pipeline Unit for Sunoco's TanQuid Acquisition
- Security Review Requirement: The German government has mandated the sale of the unit operating a vital military fuel pipeline network as a condition for Sunoco LP's acquisition of TanQuid, indicating heightened vigilance against foreign control of critical infrastructure.
- State Ownership Context: The government currently owns 51% of the TanQuid unit in question and has requested the defense ministry to acquire the remaining shares, reflecting a stringent regulatory stance on foreign acquisitions to ensure national security.
- Transaction Progress: Sunoco's purchase of TanQuid was approved and completed earlier this month, indicating that despite regulatory challenges, the deal is advancing, which may impact the future investment landscape.
- Historical Intervention Reflection: This decision echoes past interventions aimed at blocking foreign control, particularly by Chinese firms, underscoring the German government's ongoing efforts to protect national security and critical infrastructure.
Continue Reading
Energy Transfer Plans $5.5 Billion Investment for 2026, Targeting 3%-5% Distribution Growth
- Stable Cash Flow: Energy Transfer's distributable cash flow covered its distribution by 1.8 times in the first nine months of 2025, indicating a solid income base that could attract conservative investors.
- Future Investment Plans: The company plans to invest $5.5 billion in capital projects in 2026, which is expected to support a distribution growth of 3% to 5%, demonstrating its commitment to becoming a more reliable income investment.
- Historical Trust Issues: Although the distribution has recovered and surpassed pre-pandemic levels, the cut during the 2020 pandemic still raises concerns among conservative investors, potentially affecting their investment decisions.
- Alternative Competitors: For investors wary of management decisions, alternatives like Enterprise Products Partners and Enbridge offer a more stable dividend history, albeit with slightly lower yields of 6.6% and 5.8%, respectively.
Continue Reading